Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]palmitate is a radiolabeled form of palmitic acid in which the carboxyl carbon is replaced with the positron-emitting isotope carbon-11. It is used as a metabolic tracer in positron emission tomography (PET) imaging to study fatty acid metabolism in vivo. Because it is chemically identical to endogenous palmitate, it follows normal physiological pathways for fatty acids—being taken up by tissues such as heart, liver, and brain where it can be oxidized or incorporated into lipids. The mechanism of action involves tracing the uptake and subsequent metabolism (including β-oxidation and esterification) of free fatty acids at the tissue level. Its short half-life (~20 minutes) allows for dynamic studies with low radiation exposure[5][10]. Primary indications include assessment of myocardial fatty acid metabolism and research into metabolic diseases such as diabetes and obesity[4][5][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]palmitate.